ECRD 2026: Europe’s rare disease bottleneck is funding rather than science
Rare disease R&D investment is outpacing the broader biotech market, while the pipeline of innovative therapies continues to deepen. With …
Post
-
-
ECRD 2026: Navigating the rare disease diagnostic and drug development maze
The diagnostic odyssey describes the long journey that patients with rare diseases go through, starting from their first symptom up …
-
CDA data reveals trends on drug approvals and reimbursements in Canada
In April 2026, Canada’s Drug Agency (CDA) released an expanded data set offering insights and trends within its regulatory system …
-
Novo Nordisk comeback stirs as Wegovy pill wins UK approval
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved Novo Nordisk’s Wegovy (semaglutide) pill, marking another regulatory win …
-
Peptide drug conjugates: How the Indena and Chemi partnership is delivering
The pharmaceutical industry is investing heavily in therapies capable of delivering high-potent treatments to diseased cells while limiting damage to …
-
China’s NMPA approves Akeso’s gumokimab for plaque psoriasis
Akeso has received approval from China's National Medical Products Administration (NMPA) for gumokimab (AK111), an anti-Interleukin-17 (IL-17) monoclonal antibody, to …
-
FDA grants priority review for Roche’s Tecentriq combo sBLA
Roche has received the US Food and Drug Administration (FDA) priority review for its supplemental biologics licence application (sBLA) for …
-
Drug developers eye sport’s biggest stage as World Cup fever builds
As Mexico prepares to take on South Africa in the opening game of the 2026 FIFA World Cup today (11 …
-
XtalPi enters $400m partnership for small molecule therapy for GPCR target
XtalPi has entered a strategic partnership valued at more than $400m with an international biopharmaceutical company to develop oral small-molecule …
-
Beren pockets $300m to take Niemann-Pick disease therapy to market
Beren Therapeutics has secured $300m in combined funding to support the potential commercial launch of its infantile-onset Niemann-Pick disease, type …
-
EMA validates Bayer’s asundexian application for ischaemic stroke
The European Medicines Agency (EMA) has validated Bayer's marketing authorisation application for asundexian, an oral Factor XIa inhibitor, to prevent …
-
Parabilis Medicines sets biotech record with $670m IPO
Parabilis Medicines has secured the largest initial public offering (IPO) in biotech history, suggesting that an uptick of upsized public …
-
Enhance clinical trial screening and improve patient matching accuracy
Traditional approaches to patient-trial matching often rely solely on structured data, leading to inaccurate eligibility lists and missed opportunities to …
-
Coya Therapeutics CEO on ALS urgency and fast-tracking COYA 302 for patient impact
As CEO of Coya Therapeutics, Dr Arun Swaminathan is steering the company’s lead programme, COYA 302, an immune-modulating combination designed …
-
Eli Lilly continues dealmaking roll with $1bn AlzeCure agreement
Eli Lilly has inked a licensing deal worth up to $1bn with Swedish Alzheimer’s-focused biotech, AlzeCure – marking a continuation …
